Multiplex immunofluorescence analysis revealed that TLR7 was significantly upregulated by IFNα therapy in cells expressing myeloid cell markers such as CD1c+, CD68+ and CD141+ and in XCR1+ cells, a marker specific for type I DCs (Fig. 4a–c) in the tumor and the surrounding stroma (Extended Data Fig. 4c,d). The gene discussed is CD68; the disease is neoplasm.